Myeloid cell-mediated killing of BCP-ALL by IgA2 variants of CD38 or CD20 antibodies is enhanced by CD47/SIRPα interference

ABSTRACT: Characterization of therapeutic monoclonal antibodies used in the context of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). IgA2 antibodies targeting CD38 were analyzed using LC-MS/MS. Mass analysis, peptide mapping and glycoprofiling were performed to confirm sequence integrity and post-translational modifications. The analysis supports preclinical evaluation of antibody-based immunotherapies and provides insights into glycosylation relevant for effector function.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Arturo Macarron Palacios  

LAB HEAD: Arturo Macarrón Palacios

PROVIDER: PXD066660 | Pride | 2026-06-09

REPOSITORIES: Pride